Norges Bank
ALLO icon

Norges Bank’s Allogene Therapeutics ALLO Stock Holding History

Norges Bank’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-270,770
Closed -$869K – 1888
2023
Q4 		$869K Sell
270,770
-379,302
-58% -$1.08M ﹤0.01% 1874
2023
Q3 		$2.06M Sell
650,072
-119,048
-15% -$522K ﹤0.01% 1824
2023
Q2 		$3.82M Hold
769,120
– – ﹤0.01% 1780
2023
Q1 		$3.8M Sell
769,120
-114,827
-13% -$736K ﹤0.01% 1827
2022
Q4 		$5.56M Sell
883,947
-39,062
-4% -$362K ﹤0.01% 1751
2022
Q3 		$9.97M Hold
923,009
– – ﹤0.01% 1543
2022
Q2 		$10.5M Sell
923,009
-1,150,508
-55% -$10.2M ﹤0.01% 1540
2022
Q1 		$18.9M Buy
2,073,517
+444,100
+27% +$4.63M ﹤0.01% 1425
2021
Q4 		$24.3M Buy
1,629,417
+453,421
+39% +$8M 0.01% 1368
2021
Q3 		$30.2M Sell
1,175,996
-394,633
-25% -$9.37M 0.01% 1214
2021
Q2 		$41M Buy
1,570,629
+610,458
+64% +$17.4M 0.01% 1088
2021
Q1 		$33.9M Sell
960,171
-176,037
-15% -$5.94M 0.01% 1204
2020
Q4 		$28.7M Sell
1,136,208
-94,884
-8% -$3.09M 0.01% 1348
2020
Q3 		$46.4M Sell
1,231,092
-170,939
-12% -$6.44M 0.01% 877
2020
Q2 		$60M Buy
1,402,031
+357,198
+34% +$12.9M 0.02% 725
2020
Q1 		$20.3M Sell
1,044,833
-19,747
-2% -$470K 0.01% 1231
2019
Q4 		$27.7M Buy
1,064,580
+48,117
+5% +$1.33M 0.01% 1329
2019
Q3 		$27.7M Buy
1,016,463
+275,623
+37% +$7.85M 0.01% 1265
2019
Q2 		$19.9M Buy
740,840
+340,840
+85% +$9.5M 0.01% 1508
2019
Q1 		$11.6M Hold
400,000
– – ﹤0.01% 1754
2018
Q4 		$10.8M Buy
+400,000
New +$10.6M ﹤0.01% 1712

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Norges Bank's ALLO Position: Q1 2024 in Review

Norges Bank sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 270,770 shares — an estimated $869K sold.

Norges Bank first reported a position in ALLO in Q4 2018 and held it in 21 quarters. The position peaked at $60M in Q2 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Norges Bank reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Norges Bank sold 270,770 Allogene Therapeutics shares in Q1 2024, an estimated $869K.
  • Norges Bank first reported a position in Allogene Therapeutics in Q4 2018 and held it in 21 quarters.
  • Norges Bank's Allogene Therapeutics position peaked at $60M in Q2 2020.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Norges Bank's 13F filing for Q1 2024, filed 14 May 2024.